Sosei Group Corporation and Verily, an Alphabet precision health company, announced that they have entered into a strategic research collaboration. This agreement brings together the capabilities of Verily’s immune profiling and Sosei Heptares’ G-protein-coupled receptors (GPCR) structure-based drug design.
Author: Praveen Suthrum
Untangling clinical data for Janus kinase (JAK) inhibitors for the treatment of Crohn’s disease has been challenging. A team of investigators, including Tommaso Lorenzo Parigi, MD, Department of Biomedical Sciences, Humanitas University, Virginia Solitano, MD, Department of Biomedical Sciences, Humanitas University, Laurent Peyrin-Biroulet, MD, PhD, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, and Silvio Danese, MD, PhD, Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, recently examined the clinical data of 3 key and promising JAK inhibitors in this patient population.
NEW YORK (Reuters Health) – The position in which a person with gastroesophageal reflux disease (GERD) sleeps appears to have an impact on the occurrence of reflux symptoms during the night, according to a small study that suggests lying on the left side is best.
Now in our sixth year, the Crohn’s & Colitis Foundation and the American Gastroenterological Association are thrilled to announce that the Crohn’s & Colitis Congress®, will take place January 19-21, 2023, in a new and exciting location — Denver, Colorado. Join your colleagues from around the world and across the entire spectrum of clinical care and science at the premier conference on inflammatory bowel disease (IBD) as we continue our mission of transforming IBD care. Don’t miss all the excitement! We look forward to seeing you in person. Please check back for updates.
Although colorectal cancer mortality rates have declined in people over 65 due to increased diagnoses and better screening options, a concerning trend has emerged. Since the 1990s, the rate of colorectal cancer has more than doubled among adults younger than 50. Alarmingly, more younger people are dying from the disease.
Healthcare organizations were in the midst of financial and digital transformation even before the COVID-19 pandemic hit, and the pandemic only accelerated this transformation. As changes occur, the role of leadership — including CFOs — is changing as well. During a workshop sponsored by Strata Decision Technology (Strata) at the Becker’s Hospital Review 9th Annual CEO + CFO Roundtable in November, Ivan Samstein, executive vice president and CFO of the University of Chicago Medical Center, and Liz Kirk, senior vice president of strategic services at Strata, discussed challenges that lie ahead for healthcare CFOs and how they can prepare for…
Children with SARS-CoV-2 infections that present with gastrointestinal symptoms more frequently have longer hospital stays and more severe outcomes. A team, led by Andrea Lo Vecchio, MD, PhD, Department of Translational Medical Sciences, Section of Pediatrics, University of Naples Federico II, identified the clinical, radiological, and histopathologic characteristics of pediatric patients with COVID-19 with severe gastrointestinal manifestations to better forecast factors associated with severe outcomes.
Clinicians should consider sequencing risk variants for clotting problems to help tailor inflammatory bowel disease drug therapy and perioperative anticoagulation prophylaxis, new research suggests. The study found that roughly 16% of patients with IBD have a genetically increased risk for thromboembolic disease (TED), with the risk as much as 43% higher than in the general population for some IBD patients (Gastroenterology 2021;160:771-780).
Endoscopy saw a rollercoaster year in 2021, with ebbing and flowing waves of COVID-19 and elective surgeries alternately on and off the table — punctuated near year’s end by the discovery of the Omicron variant. Looking ahead to 2022, artificial intelligence (AI), robotic-assisted endoscopy and reimbursement options are sure to drive endoscopy conversations. Infection prevention will remain a hot topic, and new single-use endoscopes are poised to debut.
Mainz Biomed said on Friday that it has initiated a clinical study to evaluate the integration of mRNA biomarkers into its ColoAlert colorectal cancer test. ColoAlert is a CE-marked PCR-based test designed to detect tumor DNA in stool samples. In January, Mainz acquired an exclusive option to license a collection of mRNAs from the Universite de Sherbrooke that have shown potential as biomarkers of curable precancerous colonic polyps and treatable early-stage colorectal cancer.